HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas S Kupper Selected Research

Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)

12/2019Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.
10/2017Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
1/2017Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
11/2016Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab).
12/2015Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy.
7/2015Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
3/2015Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells.
7/2014Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.
7/2014Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission.
7/2013TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas S Kupper Research Topics

Disease

24Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
12/2019 - 12/2002
21Neoplasms (Cancer)
01/2020 - 12/2002
11Infections
01/2022 - 06/2005
7Melanoma (Melanoma, Malignant)
01/2020 - 05/2007
7Mycosis Fungoides
01/2020 - 08/2010
6Inflammation (Inflammations)
01/2021 - 02/2002
5Psoriasis (Pustulosis Palmaris et Plantaris)
01/2018 - 07/2004
5Skin Diseases (Skin Disease)
11/2017 - 06/2003
3Atopic Dermatitis (Atopic Eczema)
01/2018 - 02/2006
2Bites and Stings (Sting)
05/2019 - 01/2019
2Autoimmune Diseases (Autoimmune Disease)
01/2018 - 07/2004
2Vitiligo
01/2018 - 06/2010
2Virus Diseases (Viral Diseases)
01/2017 - 01/2017
2Pruritus (Itching)
01/2017 - 07/2013
2Hypersensitivity (Allergy)
11/2016 - 08/2012
2Cellulitis
08/2016 - 01/2016
2Erythema
07/2014 - 07/2013
2Carcinoma (Carcinomatosis)
08/2012 - 06/2003
2Sezary Syndrome (Sezary Erythroderma)
08/2010 - 08/2010
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2009 - 09/2008
2Contact Dermatitis (Eczema, Contact)
01/2008 - 10/2003
1Hypereosinophilic Syndrome (Loeffler Endocarditis)
01/2022
1Vaccinia
01/2021
1COVID-19
01/2021
1Graft vs Host Disease (Graft-Versus-Host Disease)
01/2020
1Vomiting
01/2017
1Nausea
01/2017
1Kaposi Varicelliform Eruption (Eczema Herpeticum)
01/2017
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2016
1Exanthema (Rash)
11/2016
1Leukemia
11/2016
1Lymphoma (Lymphomas)
03/2015
1Alopecia Areata
09/2014
1Testicular Neoplasms (Testicular Cancer)
07/2014
1Disease Progression
06/2014
1Genetic Predisposition to Disease (Genetic Predisposition)
01/2014
1Cutaneous Malignant Melanoma
01/2014

Drug/Important Bio-Agent (IBA)

7AntigensIBA
01/2019 - 07/2004
6T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2020 - 12/2003
6LigandsIBA
01/2019 - 02/2002
6CytokinesIBA
07/2013 - 06/2005
4Alemtuzumab (Campath)FDA Link
11/2016 - 01/2012
4Neoplasm Antigens (Tumor Antigens)IBA
08/2012 - 07/2004
3AntibodiesIBA
01/2020 - 08/2012
3E-SelectinIBA
01/2019 - 05/2007
3Biomarkers (Surrogate Marker)IBA
11/2016 - 02/2011
3Messenger RNA (mRNA)IBA
06/2014 - 02/2011
3Transforming Growth Factor beta (TGF-beta)IBA
11/2009 - 06/2005
2Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2011
2VaccinesIBA
01/2021 - 03/2012
2cyclic guanosine monophosphate-adenosine monophosphateIBA
05/2019 - 01/2019
2Mucin-1 (CA 15-3 Antigen)IBA
10/2017 - 07/2015
2Monoclonal AntibodiesIBA
11/2016 - 12/2012
2Interleukin-13IBA
04/2013 - 06/2005
2Interleukin-23 (Interleukin 23)IBA
08/2012 - 06/2003
2Peptides (Polypeptides)IBA
06/2010 - 05/2007
2Interleukin-10 (Interleukin 10)IBA
11/2009 - 06/2005
2Imiquimod (Aldara)FDA LinkGeneric
11/2009 - 09/2008
26-sulfo sialyl Lewis XIBA
09/2008 - 12/2002
1GasderminsIBA
01/2022
1tofacitinibIBA
01/2022
1Peptide Hydrolases (Proteases)FDA Link
01/2022
1Smallpox Vaccine (Vaccine, Smallpox)FDA Link
01/2021
1AllergensIBA
01/2021
1Indicators and Reagents (Reagents)IBA
01/2020
1alpha-beta T-Cell Antigen Receptors (T-Cell Receptor alpha-Chain)IBA
01/2020
1SteroidsIBA
01/2020
1VorinostatFDA Link
12/2019
1mogamulizumabIBA
12/2019
1FucosyltransferasesIBA
01/2019
1EnzymesIBA
01/2019
1IntegrinsIBA
01/2019
1Antigen Receptors (Antigen Receptor)IBA
11/2017
1DecitabineFDA Link
10/2017
1Aprepitant (Emend)FDA Link
01/2017
1LipidsIBA
01/2017
1Fatty Acid-Binding ProteinsIBA
01/2017
1Interleukin-1 (Interleukin 1)IBA
01/2017
1Pharmaceutical PreparationsIBA
11/2016
1Surface Antigens (Surface Antigen)IBA
11/2016
1Anti-Bacterial Agents (Antibiotics)IBA
08/2016
1ProcalcitoninIBA
01/2016
1Blocking AntibodiesIBA
09/2015
1Programmed Cell Death 1 ReceptorIBA
09/2015
1Janus KinasesIBA
09/2014
1Janus Kinase InhibitorsIBA
09/2014
1Histones (Histone)IBA
01/2014
1CXCR4 Receptors (CXCR4 Receptor)IBA
01/2014
1ParaffinIBA
01/2014
1Genetic Markers (Genetic Marker)IBA
01/2014
1Formaldehyde (Formol)FDA Link
01/2014
1MicroRNAs (MicroRNA)IBA
01/2014
1Immunoglobulin E (IgE)IBA
07/2013

Therapy/Procedure

15Therapeutics
11/2017 - 07/2003
3Immunotherapy
01/2018 - 05/2007
2Radiotherapy
01/2020 - 09/2005
2Brachytherapy
12/2015 - 07/2013
1Hematopoietic Stem Cell Transplantation
01/2020
1Drug Therapy (Chemotherapy)
01/2017
1Palliative Care (Palliative Therapy)
12/2015